MDMX: a novel p53‐binding protein with some functional properties of MDM2.

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53

Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562 · see citing works

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works

The P-loop — a common motif in ATP- and GTP-binding proteins

Saraste, M., Sibbald, P. R., & Wittinghofer, A. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90281-f · Cited by 2,099 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53

Baker, S. J., Markowitz, S. D., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,742 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis

Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C., Herrup, K., Lee, W., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,264 · see citing works

A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations

Cawthon, R., Weiss, R. B., Xu, G., Viskochil, D. H., Culver, M., Stevens, J., Robertson, M. A., Dunn, D. M., Gesteland, R. F., O'Connell, P., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90253-b · Cited by 1,093 · see citing works

Database of p53 gene somatic mutations in human tumors and cell lines.

Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 860 · see citing works

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells

Sarnow, P., Ho, Y.-S., Williams, J., & Levine, A. J. (1982) · Cell · doi:10.1016/0092-8674(82)90356-7 · Cited by 836 · see citing works

Presence of a Potent Transcription Activating Sequence in the p53 Protein

Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790 · see citing works

Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704 · see citing works

Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity

Ayer, D. E., Kretzner, L., & Eisenman, R. N. (1993) · Cell · doi:10.1016/0092-8674(93)90661-9 · Cited by 697 · see citing works

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.

Moll, U. M., RIOU, G. F., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 575 · see citing works

Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 562 · see citing works

Wild-type p53 binds to the TATA-binding protein and represses transcription.

Seto, E., Usheva, A., Zambetti, G. P., Momand, J. A., Horikoshi, N., Weinmann, R. S., Levine, A. J., & Shenk, T. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12028 · Cited by 504 · see citing works

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

Martin, K., Trouche, D., Hagemeier, C., Sørensen, T. S., Thangue, N. B. L., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454 · see citing works

Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

Moll, U. M., LaQuaglia, M. P., Bénard, J., & RIOU, G. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 426 · see citing works

Functional inactivation but not structural mutation of p53 causes liver cancer

Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L. T., Feitelson, M. A., & Jay, G. (1995) · Nature Genetics · doi:10.1038/ng0195-41 · Cited by 368 · see citing works

Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.

Juven‐Gershon, T., Barak, Y., Zauberman, A., George, D. L., & Oren, M. (1993) · PubMed · Cited by 332 · see citing works

Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.

Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328 · see citing works

Physical and functional interaction between WT1 and p53 proteins.

Maheswaran, S., Park, S., Bernard, A., Morris, J. F., Rauscher, F. J., HILL, D. E., & Haber, D. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5100 · Cited by 307 · see citing works

Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma.

Feitelson, M. A., Zhu, M., Duan, L., & London, W. T. (1993) · PubMed · Cited by 307 · see citing works

Human TAFII31 protein is a transcriptional coactivator of the p53 protein.

Lu, H., & Levine, A. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5154 · Cited by 301 · see citing works

The human MDM-2 oncogene is overexpressed in leukemias

Bueso-Ramos, C., Yang, Y. S., deLeon, E., McCown, P., Stass, S. A., & Albitar, M. X. (1993) · Blood · doi:10.1182/blood.v82.9.2617.bloodjournal8292617 · Cited by 294 · see citing works

Regulation of the Human hsp70 Promoter by p53

Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993) · Science · doi:10.1126/science.8418500 · Cited by 292 · see citing works

A functional p53-responsive intronic promoter is contained within the human<i>mdm2</i>gene

Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., & Oren, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.14.2584 · Cited by 276 · see citing works

The mdm-2 gene is induced in response to UV light in a p53-dependent manner.

Perry, M. E., Piette, J., Zawadzki, J., Harvey, D., & Levine, A. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11623 · Cited by 247 · see citing works

Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene

Chen, J., Lin, J., & Levine, A. J. (1995) · Molecular Medicine · doi:10.1007/bf03401562 · Cited by 214 · see citing works

What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?

Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207 · see citing works

Altered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer

LIANES, P., Orlow, I., Zhang, Z., Oliva, M. R., Sarkis, A. S., Reuter, V. E., & Cordon‐Cardo, C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1325 · Cited by 194 · see citing works

Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

Landers, J. E., Haines, D. S., STRAUSS, J. F., & George, D. L. (1994) · PubMed · Cited by 143 · see citing works

Physical and Functional Interaction between Wild-Type p53 and mdm2 Proteins

Haines, D. S., Landers, J. E., Engle, L. J., & George, D. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1171 · Cited by 136 · see citing works

Adenovirus Serotype Determines Association and Localization of the Large E1B Tumor Antigen with Cellular Tumor Antigen p53 in Transformed Cells

ZANTEMA, A., Schrier, P. I., Davis-Olivier, A., van Laar, T., Vaessen, R. T. M. J., & van der Eb, A. J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.3084 · Cited by 131 · see citing works

Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene

Zhou, M., Yeager, A., Smith, S. D., & Findley, H. W. (1995) · Blood · doi:10.1182/blood.v85.6.1608.bloodjournal8561608 · Cited by 129 · see citing works

Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53‐mediated growth arrest.

Barak, Y., & Oren, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05270.x · Cited by 119 · see citing works

p53 binds to the TATA-binding protein-TATA complex

Martin, D. W., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38619-3 · Cited by 107 · see citing works

BS69, a novel adenovirus E1A‐associated protein that inhibits E1A transactivation.

Hateboer, G., Gennissen, A., Ramos, Y. F., Kerkhoven, R. M., Sonntag-Buck, V., Stunnenberg, H. G., & Bernards, R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07318.x · Cited by 97 · see citing works

Oncogene Amplification in Urothelial Cancers With p53 Gene Mutation or MDM2 Amplification

Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W., Takahashi, R., Sugiyama, T., & Yoshida, O. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1331 · Cited by 96 · see citing works

Physical and functional interactions between p53 and cell cycle co‐operating transcription factors, E2F1 and DP1.

O’Connor, D. J., Lam, E. W. ‐., Griffin, S., Zhong, S., Leighton, L. C., Burbidge, S. A., & Lü, X. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00309.x · Cited by 94 · see citing works

The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger

Boddy, M. N., Freemont, P. S., & Borden, K. L. B. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90020-5 · Cited by 91 · see citing works

Adenovirus Serotype Determines Association and Localization of the Large E1B Tumor Antigen with Cellular Tumor Antigen p53 in Transformed Cells

ZANTEMA, A., Schrier, P. I., Davis-Olivier, A., et al. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.3084-3091.1985 · Cited by 69 · see citing works

The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein

Brown, D. R., Deb, S., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849 · Cited by 58 · see citing works

The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines

Srivastava, S. K., Tong, Y. A., Devadas, K., Zou, Z., Chen, Y., Pirollo, K. F., & Chang, E. H. (1992) · Carcinogenesis · doi:10.1093/carcin/13.7.1273 · Cited by 47 · see citing works

Physical and Functional Interaction between Wild-Type p53 and mdm2 Proteins

Haines, D. S., Landers, J. E., Engle, L. J., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1171-1178.1994 · Cited by 40 · see citing works

MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas

Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., Re, V. D., Laurino, L., Carbone, A., & Boiocchi, M. (1995) · Blood · doi:10.1182/blood.v85.11.3239.bloodjournal85113239 · Cited by 35 · see citing works

Cytogenetic evolution of mycn and mdm2 amplification in the neuroblastoma ls tumour and its cell line

Corvi, R., Savelyeva, L., Amler, L. C., Handgretinger, R., & Schwab, M. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00031-d · Cited by 31 · see citing works

Distinct Modulation of p53 Activity in Transcription and Cell-Cycle Regulation by the Large (54 kDa) and Small (21 kDa) Adenovirus E1B Proteins

Steegenga, W. T., van Laar, T., Shvarts, A., Terleth, C., van der Eb, A. J., & Jochemsen, A. G. (1995) · Virology · doi:10.1006/viro.1995.1512 · Cited by 28 · see citing works

The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein

Brown, D. R., Deb, S., Muñoz, R. M., et al. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849-6857.1993 · Cited by 22 · see citing works

GM1492 Human Diploid Skin Fibroblasts Lack the p53-Dependent G1 Cell-Cycle Checkpoint

Vanlaar, T., Steegenga, W. T., Jochemsen, A. G., Terleth, C., & VANDEREB, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2839 · Cited by 13 · see citing works

Human chromosome 11 suppresses the tumorigenicity of adenovirus transformed baby rat kidney cells: Involvement of the wilms' tumor 1 gene

Menke, A. L., van Ham, R. C. A., Sonneveld, E., Shvarts, A., Stanbridge, E. J., Miyagawa, K., van der Eb, A. J., & Jochemsen, A. G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630115 · Cited by 7 · see citing works

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

Malignant astrocytic glioma: genetics, biology, and paths to treatment

Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes &amp; Development · doi:10.1101/gad.1596707 · Cited by 2,316 · see citing works

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works

The MDM2-p53 interaction.

Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 778 · see citing works

Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · see citing works

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 717 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

The cellular response to p53: the decision between life and death

Sionov, R. V., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203130 · Cited by 600 · see citing works

Inactivation of the p53 pathway in retinoblastoma

Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway

Zhang, Y., Wolf, G. W., Bhat, K., Jin, A., Allio, T., Burkhart, W., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8902-8912.2003 · Cited by 556 · see citing works

Coping with stress: multiple ways to activate p53

Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522 · see citing works

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · see citing works

Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition

Dai, M., Zeng, S. X., Jin, Y., Sun, X., David, L. L., & Lu, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7654-7668.2004 · Cited by 495 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage

Aladjem, M. I., Spike, B. T., Rodewald, L. W., Hope, T. J., Klemm, M., Jaenisch, R., & Wahl, G. M. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70061-2 · Cited by 442 · see citing works

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398 · see citing works

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · see citing works

MDM2, an introduction.

Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 390 · see citing works

HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361 · see citing works

Activation of the p53 tumor suppressor protein

Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337 · see citing works

MDM2 interacts with MDMX through their RING finger domains

Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324 · see citing works

Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development

Migliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., & Marine, J.-C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5527-5538.2002 · Cited by 313 · see citing works

Activation and activities of the p53 tumour suppressor protein

Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 310 · see citing works

The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage

Zhang, A., Zhou, N., Huang, J., Liu, Q., Fukuda, K., Ma, D., Lü, Z., Bai, C., Watabe, K., & Mo, Y. (2012) · Cell Research · doi:10.1038/cr.2012.164 · Cited by 301 · see citing works

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · see citing works

The Roles of MDM2 and MDMX in Cancer

Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 294 · see citing works

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 284 · see citing works

Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein

Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286 · see citing works

DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities

Abuetabh, Y., Wu, H. H., Chai, C., Yousef, H. A., Persad, S., Sergi, C. M., & Leng, R. P. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00863-4 · Cited by 275 · see citing works

Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.

Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F. A. S., Ovaa, H., Abraham, T. E., Dirks, R. W., & Jochemsen, A. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.024 · Cited by 260 · see citing works

MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation

Wang, C., Ivanov, A. V., Chen, L., Fredericks, W. J., Seto, E., Rauscher, F. J., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600791 · Cited by 263 · see citing works

Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells <i>in vivo</i>

Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., & Marine, J.-C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508476103 · Cited by 260 · see citing works

ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage

Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600812 · Cited by 260 · see citing works

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 255 · see citing works

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249 · see citing works

Mechanism of p53 stabilization by ATM after DNA damage

Cheng, Q., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10556 · Cited by 248 · see citing works

Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

Riemenschneider, M. J., Büschges, R., Wolter, M., REIFENBERGER, J., Boström, J. P., Kraus, J. A., Schlegel, U. S., & Reifenberger, G. (1999) · PubMed · Cited by 247 · see citing works

MDM2 promotes ubiquitination and degradation of MDMX

Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246 · see citing works

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin

Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236 · see citing works

Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms

Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K., & Jochemsen, A. G. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve227 · Cited by 234 · see citing works

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A. G., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 233 · see citing works

p53-Mdm2--the affair that never ends

Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 231 · see citing works

p53 as a target for the treatment of cancer

Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J. P., O’Connor, D. P., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 230 · see citing works

MDMX: from bench to bedside

Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228 · see citing works

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 214 · see citing works

MdmX Protects p53 from Mdm2-Mediated Degradation

Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211 · see citing works

Mdm2 binds p73α without targeting degradation

Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212 · see citing works

Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53

Teufel, D. P., Freund, S. M. V., Bycroft, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702010104 · Cited by 207 · see citing works

miR-34 and p53: New Insights into a Complex Functional Relationship

Navarro, F., & Lieberman, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132767 · Cited by 203 · see citing works

Cellular UV damage responses—Functions of tumor suppressor p53

Latonen, L., & Laiho, M. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.04.003 · Cited by 196 · see citing works

Mdm2: The Ups and Downs

Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193 · see citing works

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193 · see citing works

mdmx is a negative regulator of p53 activity in vivo.

Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C.-Y., Zambrowicz, B., Ramírez‐Solis, R., Sands, A., et al. (2002) · PubMed · Cited by 192 · see citing works

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

Li, Q., & Lozano, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 191 · see citing works

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · see citing works

Mdmx as an essential regulator of p53 activity

Marine, J., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 186 · see citing works

Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

Ke, B., Tian, M., Li, J., Liu, B., & He, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21398 · Cited by 188 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

The p53 tumour suppressor gene

Steele, R. J., Thompson, A. M., Hall, P. A., & Lane, D. P. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00910.x · Cited by 184 · see citing works

Regulation of p53 stability and activity in response to genotoxic stress

Colman, M. S., Afshari, C. A., & Barrett, J. C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00035-1 · Cited by 181 · see citing works

Regulating the p53 system through ubiquitination

Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179 · see citing works

Control of p53 ubiquitination and nuclear export by MDM2 and ARF.

Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 176 · see citing works

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173 · see citing works

Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network

Daftuar, L., Zhu, Y. Y., Jacq, X., & Prives, C. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068667 · Cited by 173 · see citing works

An essential function of the extreme C-terminus of MDM2 can be provided by MDMX

Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170 · see citing works

The Transactivation Domains of the p53 ProteinPreprint

Raj, N., & Attardi, L. D. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 174 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation

Meulmeester, E., Pereg, Y., Shiloh, Y., & Jochemsen, A. G. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1981 · Cited by 166 · see citing works

Limiting the power of p53 through the ubiquitin proteasome pathwayPreprint

Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 165 · see citing works

Hdmx modulates the outcome of p53 activation in human tumor cells

Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163 · see citing works

ATM activates p53 by regulating MDM2 oligomerization and E3 processivity

Cheng, Q., Chen, L., Li, Z., Lane, W. S., & Chen, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.294 · Cited by 165 · see citing works

DNA damage-induced MDMX degradation is mediated by MDM2

Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K. C., & Yuan, Z.-M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308295200 · Cited by 163 · see citing works

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Qi, S., Cheng, G., Cheng, X., Xu, Z., Xu, B., Zhang, W., & Qin, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00233 · Cited by 162 · see citing works

RING Domain–Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity

Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., & Yuan, Z.-M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1313 · Cited by 156 · see citing works

Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis

Bursać, S., Brdovčak, M. C., Donati, G., & Volarević, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.014 · Cited by 154 · see citing works

Current developments of targeting the p53 signaling pathway for cancer treatment

Huang, J. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 155 · see citing works

Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development

Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155 · see citing works

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159 · see citing works

Isolation and Identification of the Human Homolog of a New p53-Binding Protein, Mdmx

Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y. F., Steegenga, W. T., Merckx, G., van Ham, R. C. A., van Oordt, C. W. M. D. H., van der Eb, A. J., & Jochemsen, A. G. (1997) · Genomics · doi:10.1006/geno.1997.4775 · Cited by 152 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.

Ramos, Y. F., Stad, R. K., Attema, J., Peltenburg, L. T. C., van der Eb, A. J., & Jochemsen, A. G. (2001) · PubMed · Cited by 149 · see citing works

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 143 · see citing works

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 147 · see citing works

Hdmx Stabilizes Mdm2 and p53

Stad, R., Ramos, Y. F. M., Little, N., Grivell, S., Attema, J., van der Eb, A. J., & Jochemsen, A. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003496200 · Cited by 145 · see citing works

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2

de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143 · see citing works

MDMX regulation of p53 response to ribosomal stress

Gilkes, D. M., Chen, L., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601424 · Cited by 142 · see citing works

Massively regulated genes: the example of TP53

Hollstein, M. C., & Hainaut, P. L. (2009) · The Journal of Pathology · doi:10.1002/path.2637 · Cited by 142 · see citing works

Regulation of p53: a collaboration between Mdm2 and MdmX

Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140 · see citing works

A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19 ARF –p53 signalingPreprint

Shvarts, A., Brummelkamp, T. R., Scheeren, F., Koh, E., Daley, G. Q., Spits, H., & Bernards, R. (2002) · Genes & Development · doi:10.1101/gad.929302 · Cited by 142 · see citing works

Reactivation of p53: from peptides to small molecules

Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 135 · see citing works

MDM2 and MDMX bind and stabilize the p53-related protein p73

Ongkeko, W. M., Wang, X. Q., Siu, W. Y., Lau, A. W. S., Yamashita, K., Harris, A. L., Cox, L. S., & Poon, R. Y. C. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80367-4 · Cited by 132 · see citing works

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

Chêne, P. (2004) · PubMed · Cited by 136 · see citing works

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134 · see citing works

The tumour suppressor RASSF1A promotes MDM2 self‐ubiquitination by disrupting the MDM2–DAXX–HAUSP complex

Song, M. S., Song, S. J., Kim, S. Y., Oh, H. J., & Lim, D. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.115 · Cited by 134 · see citing works

The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy

Liu, Y., Wang, X., Wang, G., Yang, Y., Yuan, Y., & Ouyang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.018 · Cited by 133 · see citing works

DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation

Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.-C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9608-9620.2005 · Cited by 129 · see citing works

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same EndPreprint

Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 128 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

Isolation and Identification of the Human Homolog of a New p53-Binding Protein, Mdmx

Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y. F., Steegenga, W. T., Merckx, G., van Ham, R. C. A., van Oordt, C. W. M. D. H., van der Eb, A. J., & Jochemsen, A. G. (1997) · Genomics · doi:10.1006/geno.1997.4775 · Cited by 152 · see citing works

Identification of a domain within MDMX‐S that is responsible for its high affinity interaction with p53 and high‐level expression in mammalian cells

Rallapalli, R., Strachan, G. D., Tuan, R. S., & Hall, D. J. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10535 · Cited by 45 · see citing works

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 26 · see citing works

Constitutive mdmx Expression During Cell Growth, Differentiation, and DNA Damage

Jackson, M. W., & Berberich, S. J. (1999) · DNA and Cell Biology · doi:10.1089/104454999314971 · Cited by 27 · see citing works